JPMorgan raised the firm’s price target on Ideaya Biosciences (IDYA) to $74 from $72 and keeps an Overweight rating on the shares. The firm believes the company’s early-stage updates for IDE849 and IDE397 can drive investor interest in the pipeline beyond darovasertib.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences submits IDE892 IND application to FDA
- IDEAYA Biosciences: Strategic Partnership with Servier Bolsters Financial Outlook and Validates Darovasertib Potential
- IDEAYA Biosciences: Strategic Partnerships and Financial Strength Underpin Buy Rating
- IDEAYA Biosciences Licenses Darovasertib to Servier
- Ideaya Biosciences, Servier announce exclusive darovasertib license agreement